Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 324.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.03
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SG
• Employees: 107
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): -0.03
• Shares Outstanding: 1,062,020,600
• 10 Day Avg. Volume: 299,930
• 30 Day Avg. Volume: 324,460
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: S$0.00 ▼(-100.00% Downside)

Singapore Institute of Advanced Medicine Holdings Ltd. faces critical financial issues with negative profitability and high leverage, posing significant financial risks. The technical analysis suggests a bearish trend, and the negative valuation metrics further indicate challenges. These factors contribute to a low overall stock score.

Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model

Company Description

Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) is a healthcare company based in Singapore, focusing on providing advanced medical services. The company operates within the medical and healthcare sectors, offering cutting-edge diagnostic and therapeutic services. Its core services include comprehensive cancer diagnostics, radiation therapy, and personalized treatment planning, leveraging state-of-the-art technology and specialized medical expertise.

How the Company Makes Money

The company generates revenue primarily through its healthcare services, which include diagnostic imaging, radiotherapy, and oncology treatment. These services are offered to patients directly or through partnerships with hospitals and clinics. Revenue is also derived from collaborations with medical research institutions and healthcare providers, through which the company offers its specialized expertise and advanced technological solutions. The company's earnings are significantly bolstered by its strategic partnerships with technology providers, allowing them to access and implement the latest medical technologies, which attract more patients and healthcare partners. Additionally, they may receive funding or grants from governmental or private healthcare initiatives aimed at enhancing cancer treatment capabilities in the region.

Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview

Summary

Despite revenue growth, the company faces severe financial challenges with negative profitability and margins, high leverage, and concerning cash flow issues.

Income Statement

The company has been experiencing consistent revenue growth with an increase from 2023 to 2024. However, profitability is a significant concern, as evidenced by negative gross profit and net income margins over the years. The EBIT and EBITDA margins are also negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet shows a relatively high debt-to-equity ratio, indicating significant leverage which increases financial risk. The equity ratio has improved slightly, reflecting a healthier balance between assets and liabilities, but the overall financial position remains strained due to high liabilities.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, suggesting challenges in generating cash from operations. The company has managed to reduce its capital expenditures, but the free cash flow to net income ratio is concerning, indicating potential liquidity issues.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	16.65M	16.23M	13.81M	12.92M
Gross Profit	15.36M	-2.60M	-4.31M	-2.32M
EBITDA	-13.42M	-10.78M	-8.02M	-3.06M
Net Income	-37.45M	-18.07M	-12.43M	-9.35M
Balance Sheet
Total Assets	138.76M	159.52M	174.36M	172.08M
Cash, Cash Equivalents and Short-Term Investments	3.16M	11.05M	15.84M	10.29M
Total Debt	46.10M	80.77M	87.30M	92.26M
Total Liabilities	57.01M	114.60M	120.31M	112.90M
Stockholders Equity	81.74M	44.93M	54.05M	59.18M
Cash Flow
Free Cash Flow	-14.80M	-19.89M	-11.26M	-9.72M
Operating Cash Flow	-14.26M	-5.45M	-7.15M	-4.26M
Investing Cash Flow	-263.72K	-1.45M	3.72M	-5.25M
Financing Cash Flow	6.64M	2.11M	9.18M	10.66M

Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 35.56 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:9G2.

Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSL	67 Neutral	$1.98B	30.61	6.20%	2.40%	8.90%	4.57%
9G2	44 Neutral		―		―	―	―
Sector *	44 Neutral	$6.72B	-1.09	0.00%	―	0.00%	0.00%

Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events

Singapore Institute of Advanced Medicine Unveils Strategic Initiatives for Growth

The Singapore Institute of Advanced Medicine Holdings Ltd. has announced strategic initiatives to improve the utilization of its proton beam and photon radiation therapy facilities and ensure operational sustainability. The company plans to focus on business development, explore collaborations with other healthcare providers in Singapore and the ASEAN region, and implement cost-saving measures. These steps are expected to enhance the company’s market presence and financial performance.